Social Media Content Creators Fueling Parallel Market for Unlicensed Weight-Loss Drug

An underground economy for unapproved weight-loss drugs is being driven by TikTok fitness influencers and sellers on messaging platforms, based on new investigations.

Experimental Treatment Acquiring Traction Via Social Media

The experimental drug, which remains in research studies, is being advertised by online personalities for its supposed fat-burning effects. Followers are encouraged to message these profiles directly for source information, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Separately, a flourishing market exists on Telegram, where groups with thousands of participants share “before and after” images, injection guides and claims of rapid British shipping. Sellers promote the substance there before directing customers to WhatsApp for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injectable created by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies indicate it could help patients lose up to 25% of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the successor to Ozempic.

Medical Professionals Express Worries

Nevertheless, physicians and pharmacists have cautions that the sale of what is still an unapproved medication in the UK is a cause for concern and could lead to individuals administering products of unknown origin.

Several experts said the popularity for the experimental drug could be linked to the rising price of licensed slimming products such as Mounjaro.

Regulatory Status and Implementation

Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Several influencers attempt to circumvent the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and distribution can still violate medicines, advertising, and customer laws, potentially leading to fines, legal action or prison.

Platform Response and Content Removal

Based on the social media company, the platform has removed problematic content and prohibited associated hashtags and search suggestions. The company said it was dedicated to keeping the service safe and investing in strengthening enforcement strategies.

Digital Trading Operations

Investigations also found communities with up to 9,000 participants selling the experimental drug using the platform's integrated search feature, which functions like a online catalog. Typing “retatrutide” instantly brings up channels with thousands of users, filled with images of weight loss, glowing reviews and step-by-step guides for preparing or injecting at residence.

Within minutes of entering one community, a vendor posted WhatsApp details, where most purchases take place. The seller provided an guidebook and promised delivery within 48 hours. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one asked about body mass, health issues or past usage.

Item Information and Pricing

Within these communities, messages show dark colored parcels with Royal Mail labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with sterile water, or pre-filled pens typically sold at £160 for 20mg. When asked how much time a pen should be used, sellers give conflicting answers ranging from a several days to “depends on your body”.

Platform Moderation and Security Measures

A representative for the messaging service stated it actively moderated harmful material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are administering substances they cannot confirm. Although the research behind retatrutide is valid, these online versions may not contain what they advertise,” said a pharmacy expert, the director of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in interest to current cost increases for authorized weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to online platforms. But fake injections are highly dangerous. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.

Her staff has previously seen individuals harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Producer Position

A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they explained, adding that any item “falsely representing itself as a Lilly experimental substance not yet approved … may subject patients to potentially significant health risks”.